|
Before this decade is over, doctors may be able to cure type
1 diabetes by encouraging the body to regenerate its own insulin-producing
cells. The possibility of a cure, announced during National
Diabetes Awareness Month, is based on study results recently
published in the November 14 issue of Science magazine.
The announcement was made by Massachusetts General Hospital
(MGH) and the Iacocca Foundation, a leading nonprofit group
dedicated to diabetes research, and an ardent supporter of
the study.
"What we have been able to do changes the long-standing
belief that adult islet tissue regeneration would not be robust
or have a long-lasting impact on blood sugar control,"
says Denise Faustman, MD, PhD, principal investigator of the
study. "We have successfully demonstrated that we can
re-grow cells inside the body in a naturally occurring model."
Type 1 diabetes is a disease in which the body's immune system
attacks its insulin-producing cells. These cells are necessary
for converting the body's blood sugar, or glucose, to energy.
With time, the accumulation of glucose in the blood can lead
to heart disease, kidney failure, blindness and loss of limbs.
In addition to the almost two million Americans with type
1 diabetes, approximately 30,000 individuals - mostly children
- are diagnosed with the disease each year. The annual cost
associated with the disease exceeds $20.4 billion in the U.S.
alone, according to the American Diabetes Association.
For cell regeneration to occur, the faulty immune cells that
attack the body must first be destroyed. In a previous study,
Dr. Faustman demonstrated the effectiveness of using a naturally
occurring protein (TNH-alpha antagonists) to kill the immune
cells in type 1 diabetic mice. She and her team then injected
healthy donor spleen cells to train new immune cells not to
attack the insulin-producing islets. Researchers expecting
to transplant donor islet cells discovered that healthy islets
spontaneously reappeared, suggesting that tissue regeneration
was taking place. The new study published in Science confirmed
the re-growth process.
"Dr. Faustman's research has significant implications
not only to the future of diabetes treatment, but also to
other autoimmune diseases," says Kathryn Iacocca Hentz,
president of the Iacocca Foundation. "It may someday
be possible to apply her technique in reversing rheumatoid
arthritis, multiple sclerosis and lupus."
Dr. Faustman is director of the immunobiology laboratory
at MGH, a teaching hospital affiliated with Harvard Medical
School. MGH conducts the largest hospital-based research program
in the U.S., with an annual research budget of more than $350
million. In 1994, MGH formed an affiliation with Brigham and
Women's Hospital to form Partners HealthCare system, an integrated
health care delivery system.
|